Dr. Reddy's Laboratories Stock Forecast, Price & News

-0.05 (-0.07 %)
(As of 06/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume95,083 shs
Average Volume176,563 shs
Market Capitalization$11.92 billion
P/E Ratio45.96
Dividend Yield0.38%
30 days | 90 days | 365 days | Advanced Chart
Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Dr. Reddy

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists; and partnership with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India. The company was founded in 1984 and is headquartered in Hyderabad, India.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.18 out of 5 stars

Medical Sector

997th out of 2,105 stocks

Pharmaceutical Preparations Industry

487th out of 832 stocks

Analyst Opinion: 1.5Community Rank: 2.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Dr. Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

Is Dr. Reddy's Laboratories a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Dr. Reddy's Laboratories stock.
View analyst ratings for Dr. Reddy's Laboratories
or view top-rated stocks.

What stocks does MarketBeat like better than Dr. Reddy's Laboratories?

Wall Street analysts have given Dr. Reddy's Laboratories a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Dr. Reddy's Laboratories wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Dr. Reddy's Laboratories' next earnings date?

Dr. Reddy's Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Dr. Reddy's Laboratories

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories Limited (NYSE:RDY) posted its quarterly earnings results on Thursday, May, 13th. The company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.51 by $0.05. Dr. Reddy's Laboratories had a net margin of 10.11% and a trailing twelve-month return on equity of 14.32%.
View Dr. Reddy's Laboratories' earnings history

How has Dr. Reddy's Laboratories' stock price been impacted by COVID-19 (Coronavirus)?

Dr. Reddy's Laboratories' stock was trading at $40.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RDY stock has increased by 78.5% and is now trading at $71.69.
View which stocks have been most impacted by COVID-19

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories announced an annual dividend on Thursday, July 9th. Stockholders of record on Friday, January 1st will be paid a dividend of $0.3304 per share on Friday, July 10th. This represents a yield of 0.5%. The ex-dividend date of this dividend is Friday, July 10th. This is an increase from Dr. Reddy's Laboratories's previous annual dividend of $0.27.
View Dr. Reddy's Laboratories' dividend history

Is Dr. Reddy's Laboratories a good dividend stock?

Dr. Reddy's Laboratories pays an annual dividend of $0.27 per share and currently has a dividend yield of 0.38%. The dividend payout ratio of Dr. Reddy's Laboratories is 13.43%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 8.31% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.
View Dr. Reddy's Laboratories' dividend history.

What price target have analysts set for RDY?

3 analysts have issued 1 year target prices for Dr. Reddy's Laboratories' stock. Their forecasts range from $70.00 to $70.00. On average, they anticipate Dr. Reddy's Laboratories' stock price to reach $70.00 in the next twelve months. This suggests that the stock has a possible downside of 2.4%.
View analysts' price targets for Dr. Reddy's Laboratories
or view top-rated stocks among Wall Street analysts.

Who are Dr. Reddy's Laboratories' key executives?

Dr. Reddy's Laboratories' management team includes the following people:
  • Mr. Gunupati Venkateswara Prasad B.E., Co-Chairman, MD & Member of Management Council (Age 61, Pay $1.96M)
  • Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 54, Pay $1.26M)
  • Mr. Erez Israeli M.B.A., CEO & Member of the Management Council (Age 53, Pay $1.53M)
  • Mr. Deepak Sapra M.B.A., Sr. VP, Global Head PSAI Bus. & Member of Management Council (Age 46)
  • Mr. M. V. Ramana M.B.A., MBA, CEO of Branded Markets - India & Emerging Countries and Member of Management Council (Age 52)
  • Dr. Anil Namboodiripad, Sr. VP, Head of Proprietary Products, Head of Promius Pharma & Member of Management Council (Age 54)
  • Ms. Archana Bhaskar B.Sc., M.B.A., EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council (Age 54)
  • Mr. Sauri Gudlavalleti B.Tech., Sr. VP, Global Head of Integrated Product Devel. Organization & Member of Management Council (Age 43)
  • Mr. Yugandhar Puvvala M.B.A., Sr. VP, Global Head Global Supply Chain & Member of Management Council (Age 50)
  • Mr. Sanjay Sharma B.Tech., Exec. VP, Global Head of Global Manufacturing & Member of Management Council (Age 53)

What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?

528 employees have rated Dr. Reddy's Laboratories CEO G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among Dr. Reddy's Laboratories' employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Dr. Reddy's Laboratories' key competitors?

What other stocks do shareholders of Dr. Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), Vedanta (VEDL), HDFC Bank (HDB), Alibaba Group (BABA), GlaxoSmithKline (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE).

What is Dr. Reddy's Laboratories' stock symbol?

Dr. Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

Who are Dr. Reddy's Laboratories' major shareholders?

Dr. Reddy's Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional investors include Royal Bank of Canada (2.03%), Renaissance Technologies LLC (1.23%), BlackRock Inc. (0.79%), Bank of Montreal Can (0.44%), Morgan Stanley (0.37%) and Dimensional Fund Advisors LP (0.34%).

Which institutional investors are selling Dr. Reddy's Laboratories stock?

RDY stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Schroder Investment Management Group, Grantham Mayo Van Otterloo & Co. LLC, Northern Trust Corp, Prudential Financial Inc., Acadian Asset Management LLC, and Royal Bank of Canada.

Which institutional investors are buying Dr. Reddy's Laboratories stock?

RDY stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Canada Pension Plan Investment Board, Bank of Montreal Can, Mitsubishi UFJ Trust & Banking Corp, JPMorgan Chase & Co., Amundi Asset Management US Inc., and Bamco Inc. NY.

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dr. Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $71.69.

How much money does Dr. Reddy's Laboratories make?

Dr. Reddy's Laboratories has a market capitalization of $11.92 billion and generates $2.59 billion in revenue each year. The company earns $258.51 million in net income (profit) each year or $2.01 on an earnings per share basis.

How many employees does Dr. Reddy's Laboratories have?

Dr. Reddy's Laboratories employs 21,650 workers across the globe.

When was Dr. Reddy's Laboratories founded?

Dr. Reddy's Laboratories was founded in 1984.

What is Dr. Reddy's Laboratories' official website?

The official website for Dr. Reddy's Laboratories is www.drreddys.com.

Where are Dr. Reddy's Laboratories' headquarters?

Dr. Reddy's Laboratories is headquartered at 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034.

How can I contact Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]

This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.